ECSP088166A - Composiciones en micro partículas del inhibidor de topoisomerasa i 7-ter-butoxiiminometilcamptotecina - Google Patents

Composiciones en micro partículas del inhibidor de topoisomerasa i 7-ter-butoxiiminometilcamptotecina

Info

Publication number
ECSP088166A
ECSP088166A EC2008008166A ECSP088166A ECSP088166A EC SP088166 A ECSP088166 A EC SP088166A EC 2008008166 A EC2008008166 A EC 2008008166A EC SP088166 A ECSP088166 A EC SP088166A EC SP088166 A ECSP088166 A EC SP088166A
Authority
EC
Ecuador
Prior art keywords
inhibitor
compositions
topoisomerasa
butoxiiminometilcamptotecina
ter
Prior art date
Application number
EC2008008166A
Other languages
English (en)
Inventor
Oskar Kalb
Isabel Ottinger
Wolfgang Wirth
Walter Stebler
Agnes Taillardat
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37056484&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP088166(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP088166A publication Critical patent/ECSP088166A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a composiciones farmacéuticas en micropartículas, en donde el agente activo es un inhibidor de topoisomerasa I, en particular 7-t-butoxiiminometilcamptotecina, que es útil para el tratamiento y la prevención de enfermedades proliferativas, incluyendo cáncer.
EC2008008166A 2005-08-10 2008-02-08 Composiciones en micro partículas del inhibidor de topoisomerasa i 7-ter-butoxiiminometilcamptotecina ECSP088166A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US70713905P 2005-08-10 2005-08-10

Publications (1)

Publication Number Publication Date
ECSP088166A true ECSP088166A (es) 2008-03-26

Family

ID=37056484

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008008166A ECSP088166A (es) 2005-08-10 2008-02-08 Composiciones en micro partículas del inhibidor de topoisomerasa i 7-ter-butoxiiminometilcamptotecina

Country Status (20)

Country Link
EP (1) EP1915132A1 (es)
JP (1) JP2009504616A (es)
KR (1) KR20080034989A (es)
CN (1) CN101287448A (es)
AR (1) AR055602A1 (es)
AU (1) AU2006277879A1 (es)
BR (1) BRPI0614757A2 (es)
CA (1) CA2618084A1 (es)
EC (1) ECSP088166A (es)
GT (1) GT200600364A (es)
IL (1) IL189076A0 (es)
MA (1) MA29735B1 (es)
MX (1) MX2008001965A (es)
NO (1) NO20081213L (es)
PE (1) PE20070232A1 (es)
RU (1) RU2008108885A (es)
TN (1) TNSN08062A1 (es)
TW (1) TW200800195A (es)
WO (1) WO2007017514A1 (es)
ZA (1) ZA200800726B (es)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5726181A (en) * 1995-06-05 1998-03-10 Bionumerik Pharmaceuticals, Inc. Formulations and compositions of poorly water soluble camptothecin derivatives
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
IT1306129B1 (it) * 1999-04-13 2001-05-30 Sigma Tau Ind Farmaceuti Esteri della l-carnitina o di alcanoil l-carnitine utilizzabili comelipidi cationici per l'immissione intracellulare di composti
EP1269994A3 (en) * 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmaceutical compositions comprising drug and concentration-enhancing polymers
GT200500310A (es) * 2004-11-19 2006-06-19 Compuestos organicos

Also Published As

Publication number Publication date
PE20070232A1 (es) 2007-04-09
JP2009504616A (ja) 2009-02-05
EP1915132A1 (en) 2008-04-30
TNSN08062A1 (en) 2009-07-14
AR055602A1 (es) 2007-08-29
KR20080034989A (ko) 2008-04-22
MX2008001965A (es) 2008-03-26
MA29735B1 (fr) 2008-09-01
CA2618084A1 (en) 2007-02-15
ZA200800726B (en) 2009-08-26
TW200800195A (en) 2008-01-01
WO2007017514A1 (en) 2007-02-15
IL189076A0 (en) 2008-08-07
CN101287448A (zh) 2008-10-15
BRPI0614757A2 (pt) 2011-04-12
NO20081213L (no) 2008-05-13
AU2006277879A1 (en) 2007-02-15
GT200600364A (es) 2007-03-19
RU2008108885A (ru) 2009-09-20

Similar Documents

Publication Publication Date Title
BRPI0809164B8 (pt) Composição para administração tópica e composição farmacêutica compreendendo a referida composição
PH12017501306A1 (en) Inhibitors of histone demethylases
DOP2007000053A (es) Compuestos de tetrahidropiridotienopirimidina y métodos para su empleo
IN2012DN02018A (es)
CR20140108A (es) Compuesto de ciclopropanoamina
PA8770101A1 (es) Amidas de 4-aril-1,4-dihidro-1, 6-naftiridina sustituidas y su uso
GT200600194A (es) Composiciones farmaceuticas conteniendo imatinib y un componente de liberacion prolongada
UY32456A (es) Composicion famaceutica, forma farmaceutica, procedimiento para su preparación, metodos de tratamiento
MY198422A (en) Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
CL2008001633A1 (es) Compuestos derivados de pirrolidin-3-carboxamida; composición farmacéutica; y uso comominhibidores de erk para el tratamiento del cancer.
BR112012009376B8 (pt) composição farmacêutica sólida compreendendo um inibidor de sglt-2 e sua forma de dosagem farmacêutica
GT200800250A (es) Arilimidazolonas y ariltriazolonas sustituidas como inhibidores de receptores de vasopresina
CL2010001474A1 (es) Compuestos derivados de tiofeno o tiazol sustituidos, inhibidores de pi3k; composicion farmaceutica; utiles en el tratamiento del cancer, inflamacion y en el tratamiento de trastornos cardiovasculares.
CL2014001838A1 (es) Compuestos derivados de fluormetil-5,6-dihidro-4h-[1,3]oxazin-2-ilamina, como inhibidores de la bace1; su proceso de obtencion; composicion farmaceutica que los contiene; y su uso para el tratamiento terapeutico y/o profilactico de la enfermedad de alzheimer, esclerosis lateral amiotrofica, cancer, enfermedades cardiovasculares y enfermedades gastrointestinales, entre otras.
CR11684A (es) Dihidropirazolonas sustituidas de hif-propil-4- como inhibidores hidroxilasa
CR9427A (es) Combinacion terapeutica en casos de hiperplasia prostatica benigna
HN2010002518A (es) Composicion farmaceutica que comprende una sal de estroncio, vitamina d y una ciclodextrina
DOP2010000302A (es) Antagonistas de la trayectoria hedgehog de ftalazina disustituida
BRPI1015539A2 (pt) composições e métodos para tratamento de queimaduras
CU24349B1 (es) Composiciones que comprenden 2,3-dihidroimidazo [1,2-c] quinazolinas sustituidas útiles para el tratamiento del cáncer
BRPI0518448A2 (pt) composiÇÕes farmacÊuticas compreendendo um derivado de camptotecina
CL2007003356A1 (es) Compuestos derivados de benzopirazoles; proceso para la preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos y otro agente activo; y su uso para el tratamiento del asma, inflamacion, entre otras enfermedades.
DOP2007000043A (es) Derivados de cromanol sustituidos y su uso
UY33530A (es) Composiciones farmacéuticas para el tratamiento de enfermedades respiratorias e inflamatorias
UY30675A1 (es) Metodos para el tratamiento de la depresion